Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy

Health care costs, health care resource utilization, and time to next treatment were compared among patients with chronic lymphocytic leukemia initiated on front-line ibrutinib single agent (N = 322) or chemoimmunotherapy (N = 839). Ibrutinib was associated with lower total health care costs driven...

Descripción completa

Detalles Bibliográficos
Autores principales: Emond, Bruno, Sundaram, Murali, Romdhani, Hela, Lefebvre, Patrick, Wang, Song, Mato, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199924/
https://www.ncbi.nlm.nih.gov/pubmed/31678080
http://dx.doi.org/10.1016/j.clml.2019.08.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199924/
https://www.ncbi.nlm.nih.gov/pubmed/31678080
http://dx.doi.org/10.1016/j.clml.2019.08.004

Ejemplares similares